Clarion News

Virtual ASCO 2020 Highlights

SHARE:

The coronavirus pandemic forced ASCO to shift their 2020 Annual Meeting into an online format for the first time, but the conference remained a key forum for cancer innovation—an area to which Clarion is committed. We are pleased to share our perspectives on some of the most impactful new data at the virtual event:

Key Takeaways

  • IO expands vertically: Checkpoint inhibitors rack up more successes in the frontline setting
  • IO expands horizontally: Data support new immune MoAs, combinations, and indications
  • Targeted therapy: EGFR and HER2 therapies expand their reach, and novel mechanisms emerge
  • Hematology-oncology: Excitement continues for BCMA in myeloma, CD47 in AML/MDS, and other novel approaches
  • COVID-19: Real-world data confirms the new threat to cancer patients

 

Click HERE to read the full perspectives for the 2020 ASCO Virtual Annual Meeting

Is Clarion the right place to advance your career?

Find out more about joining Clarion’s team of innovation advisors.

A life sciences strategy and organizational consultancy that collaborates with its clients to envision, craft and enable growth through innovation and leadership.